ALFA Finder
16:53 IST
BSE
Other Announcement
Concord Drugs Other Announcement
Concord Drugs Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per SEBI regulations.
Concord Drugs Ltd
- Share price
- ₹71.11
- Market cap
- ₹93.69 Cr
- Revenue (annual)
- ₹78.74 Cr
- Net profit (annual)
- ₹1.06 Cr
- P/E (TTM)
- 45.7×Sector 43.8×
- Promoter holding
- 45.08%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 6Financial Results 4Board Meeting Date 3Debt & Borrowing 2Annual General Meeting 2Annual Report 1
Time
6 announcements with these filters
19:33 IST
BSE
Other Announcement
Concord Drugs Other Announcement
Concord Drugs Limited is notifying shareholders about the annual report web-link as per Regulation 36(1)(b). Shareholders are urged to update their email addresses.
22:59 IST
BSE
Other Announcement
Concord Drugs Other Announcement
Concord Drugs Ltd submitted its quarterly shareholding pattern for the period ended June 30, 2026, pursuant to SEBI Regulation 31(1)(b). This is a routine periodic disclosure.
21:46 IST
BSE
Other Announcement
Concord Drugs Other Announcement
Concord Drugs Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, as required under SEBI regulations.
23:13 IST
BSE
Other Announcement
Concord Drugs Other Announcement
Concord Drugs Limited filed its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report notes minor delays in certain regulatory submissions.
18:10 IST
BSE
Other Announcement
Concord Drugs Other Announcement
Concord Drugs Limited confirmed it does not fall under the 'Large Corporate' category for the financial year ended March 31, 2026. Consequently, the company is not subject to the fund-raising requirements or annual disclosure obligations mandated by SEBI for Large Corporates. The company reported zero outstanding borrowings as of the specified date.